Kerecis Ltd.
16
3
7
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 16 trials
100.0%
+13.5% vs industry average
19%
3 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Evaluating Whether Intact Fish Skin Graft Can Decrease the Need for Autograft in the Treatment of Deep Partial-Thickness Burns
Role: lead
Gender Affirming Vaginoplasty With Tubularized Augmented Peritoneal Cap (TAPCap) Utilizing Fish Skin Xenograft (Kerecis™)
Role: collaborator
Evaluating the Durability of Closure for Venous Leg Ulcers
Role: lead
Evaluating Intact Fish Skin Graft and Standard of Care Versus Standard of Care Alone in Nonhealing Venous Leg Ulcers
Role: lead
Kerecis Case Registry for SurgiBind : Soft Tissue Reinforcement
Role: lead
AFS Compared to AHC in Treatment of Necrotizing Fasciitis NF
Role: lead
Kerecis Real-World Fish Skin Graft Registry
Role: lead
Prospective Case Registry for Wounds
Role: lead
Healing of Punch Graft Wounds. Comparative Study Between MariGen and Oasis: a Non-inferiority Study
Role: lead
Interventional Clinical Trial Comparing Kerecis Omega3 Wound Versus SOC in Diabetic Foot Wounds
Role: collaborator
Kerecis Omega3 Wound Plus SOC vs. SOC Alone in Treating Severe Diabetic Foot Ulcers and Forefoot Amputations
Role: lead
Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19
Role: lead
Fish Skin Compared to Cadaver Skin as Temporary Cover for Full Thickness Burns
Role: lead
Omega3 Wound Fish Skin Graft in the Treatment of DFUs
Role: lead
A Clinical Trial to Evaluate Kerecis Oral™ Compared to Autogenous Free Gingival Graft (AFGG) Tissue to Augment Gingival Soft Tissue and Wound Healing
Role: lead
Use of Fish Skin Extracellular Matrix (ECM) to Facilitate Chronic Wound Healing
Role: lead
All 16 trials loaded